Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.
PVT-2201-303: CLARITY Study for Non-Infectious Uveitis - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called brepocitinib (the study drug) is a safe and effective option people with non-infectious uveitis (NIU).
What is the Condition Being Studied?
Non-Infectious Uveitis (NIU)
Who Can Participate in the Study?
Adults ages 18-75 who:
- Are diagnosed with NIU
- Do not have high eye pressure
- Have not been diagnosed or treated for any type of cancer in the past 5 years
For more information, contact the study team at DEC-RA@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will get a random assignment (like a coin flip) to either:
- Take the study drug; OR
- Take a placebo (inactive substance with no drug)
Study participation is expected to last for up to 104 weeks (about 2 years). At first, visits will be scheduled about every 2 to 4 weeks. Later in the study, visits will be scheduled every 4 to 12 weeks. You will not need to make any changes to your routine medications if you join this study.
Study Details
Full Title
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis - CLARITY
Principal Investigator
Ophthalmologist
Protocol Number
IRB:
PRO00115979
NCT:
NCT06431373
Phase
Phase
III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment Soon